The OSIRIS-REx spacecraft's name has been changed to OSIRIS-APEX for its new mission to asteroid Apophis. See its journey to the asteroid in this orbit animation. Credit: NASA's Scientific ...
To hear Silicon Valley tell it, artificial intelligence is outgrowing the planet that gave birth to it. Data centers will account for nearly half of U.S. electricity demand growth between now and 2030 ...
With outstanding customization options, an epic sensor, wireless connectivity, and stunningly lightweight, the Pathfinder is exemplary. Really, it's only mildly let down by its price and the fact that ...
As artificial intelligence drives the need for vastly more computing storage and processing power, interest in space-based data centers has spiked. Although several startup companies, such as ...
Like Pokémon, it’s fun to try and snatch up every new custom like button in YouTube’s redesign. One user put together an animated list of every new icon. Part of YouTube’s broader new design on ...
Reflect Orbital says their light-on-demand idea has generated significant interest from commercial and government customers. When you purchase through links on our site, we may earn an affiliate ...
INDIANAPOLIS -- Indianapolis Colts backup quarterback Anthony Richardson suffered an orbital fracture to his eye prior to Sunday's 31-27 victory over the Arizona Cardinals, according to coach Shane ...
There’s something weird in the water in Indianapolis lately. The Colts had a couple of unusual injuries during pregame warmups before Sunday’s win over the Cardinals. Cornerback Charvarius Ward ...
Oct 10 (Reuters) - Drugmaker Bristol Myers Squibb (BMY.N), opens new tab said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to ...
The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a ...
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases Transaction further ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback